E-Mail
By André Julião | Agência FAPESP - A drug used to treat pulmonary hypertension significantly reduced the capacity of tumor cells to migrate and invade other tissues in trials involving pancreatic, ovarian, breast cancer, and leukemia cell lines. Furthermore, in mice with an aggressive form of breast cancer, the drug reduced the incidence of metastasis in the liver and lungs by 47% and lengthened survival compared with untreated animals.
The study is
Scientific Reports. The drug ambrisentan is an inhibitor of the endothelin type A receptor, which is known to play a role in vasoconstriction, so the drug is used to treat pulmonary hypertension [
Pulmonary hypertension drug may become a treatment option for cancer
A drug used to treat pulmonary hypertension significantly reduced the capacity of tumor cells to migrate and invade other tissues in trials involving pancreatic, ovarian, breast cancer, and leukemia cell lines. Furthermore, in mice with an aggressive form of breast cancer, the drug reduced the incidence of metastasis in the liver and lungs by 47% and lengthened survival compared with untreated animals.
The study is published in
Scientific Reports. The drug ambrisentan is an inhibitor of the endothelin type A receptor, which is known to play a role in vasoconstriction, so the drug is used to treat pulmonary hypertension [